WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 10, Issue 12, 617-628. Review Article ISSN 2277– 7105

ORPHAN DISEASES AND THEIR REGULATORY ROLES GLOBALLY

Tanuj Upadhyay*, Amansharma[1], A. N. Nagappa[2] and Shvetank Bhatt[3]

*Amity Institute of Pharmacy Amity University Madhya Pradesh (AUMP), Gwalior-474005, India.

[1,2,3]Amity Institute of Pharmacy Amity University Madhya Pradesh (AUMP), Gwalior-474005, India.

Article Received on
10 August 2021,

Revised on 31 August 2021,
Accepted on 21 Sept. 2021

DOI: 10.20959/wjpr202112-21766

***Corresponding Author**
Tanuj Upadhyay
Amity Institute of Pharmacy Amity University Madhya Pradesh (AUMP), Gwalior-474005, India.

ABSTRACT

The uncommon malady of medication improvement in India for the treatment of glioblastoma, multiforme, nocardiosis, Tourette disorder, and so forth orphan medication pharmaceutical specialists are utilized. Indian govt. can likewise invest their amounts of energy to the local pharmaceutical organization to make or research on the pharmaceutical orphan product or they need to begin ODA(ORPHAN DRUG ACT) Orphan sedate development is additionally an exorbitant procedure so industry shows the least enthusiasm for developing this sort of medication. The danger of infection increases with the high population, although multicentric preliminaries can short out this issue, about 450 uncommon ailments are found in India. The primary sort of uncommon malady workshop was directed by the INSA to develop a Scientific Program for Research on Rare Diseases" in 2016 however now various advances are as of now started by non govt. Establishment of a scholastic foundation and organization. Among the total populace 6-8% populace is experiencing the uncommon sickness or the orphan drug is a pharmaceutical operator that is utilized to treat an uncommon ailment. Today there are 5000 infections recorded on the planet. The proportion of the uncommon illness is considerably more in comparison to Japan, USA and Australia. A sickness that influences 5in 10000 is the meaning of uncommon illness in Europe. R and D are continuously working to adapt to the uncommon illness. It's a sort of irresistible sickness (virus, pathogens) and so on are involved.

KEYWORDS: Orphan Drug Act (ODA), Orphan drug, Orphan disease, Nocardiosis, Tourette disorder, Glioblastoma, Multiforme etc.

INTRODUCTION

The orphan drug disease every country has specified criteria for defining rare disease and orphan drug used in it orphan in connection with the pediatric populace who were being sidelined from clinical preliminary as efficacy and counteraction of medicine.[1] Almost 80% of rare disease-related with disturbances in genomic sequence alteration in the genes rest 20% is initiated by (bacteria, virus, and infection) orphan drugs are rarely available or highly expensive some rare drugs are often present for the researching work in the pharmaceutical company are lagging behind due to un sponsorship no funding raised. If we look at how deficiency of orphan drugs can create the situation of crisis they proved boon to us leaving behind industries must focus on starting with small- small initiatives A restorative item assigned as an uncommon medication is one that has been grown explicitly to treat an uncommon ailment.[2] Side effects of some uncommon illnesses may show up during childbirth or in youth, including puerile spinal strong decay, lysosomal capacity issue, dealing with the strides of Australia Europe and japan India should accentuation on the pharmaceutical industry to get including in looking of uncommon illness drug since the presentation of ODA, about 1100 medications and organic items have been assigned as rare items. The FDA has affirmed more than 231 of these for advertising, in this manner encouraging treatment for an expected 11 million patients in the USA. Additionally, the FDA has so far offered 370 additional painting clinical awards totaling more than $150 million for orphan item developers. For some monetary reason, the development of medication for the treatment of illness in developing countries is lingering behind.[3]

Orphan Disease and Drug Used In It

ACROMEGALY

Affecting 2–11 people per million annually. Worldwide**,** Octreotide treatment of acromegaly diminishes GH and IGF-1 focuses, yet in addition seems to lessen the size of the tumor in about 60% of cases. The somatostatin analogs are increasingly productive in the essential treatment of acromegalic patients, because of the way that essential treatment is as compelling as an optional treatment yet essential treatment has little points of interest when contrasted and auxiliary octreotide treatment on the grounds that no careful treatment is required previously.[4]

OVARIAN CANCER

Around the world, the number of passes from ovary malignancy was 4.4% in 2018. In 2020, the US has assessed 21,750 new instances of ovarian malignant growth and assessed 13,940 because of this deadly sickness. Amifostine is utilized to shield the kidneys from the destructive impacts of chemotherapy tranquilize cisplatin in patients that get this medicine for the treatment of ovarian malignant growth. Amifostine is likewise used to diminish dryness in the mouth brought about by rad Amifostine is additionally in some cases used to forestall and diminish reactions related to certain chemotherapy prescriptions or radiation treatment of certain sorts of platelet diseases. treatment after the medical procedure for head and neck cancer

SCURVY

It happens all the more regularly and is uncommon contrasted with other nutritional deficiencies the creating scene in relationship with ailing health. Rates among outcasts are accounted for at 5 to 45 percent**.** A researchable study has represented ascorbic acid (vitamin c) with some anti-inflammatory drugs are used in different doses from Oral nutrient C, 600 mg day by day for multi-week quickly prompted goals of the skin injuries and vague grumblings of disquietude, joint throb, and shortcoming. The treatment proceeded at a lower portion of 100 mg/day. Ensuring dietary appraisal indicated an extremely low day-by-day admission of ascorbic corrosive of under 10 mg every day. This was because of a willful low buildup diet received by the patient in light of infrequent colicky stomach torments.[5]

CUSHING DISEASE

It is accounted for that the rate of endogenous Cushing condition is around 13 for every million individuals yearly Mifepristone, initially utilized as a progesterone receptor adversary Cushing's disorder realized by mifepristone treatment are joined by an ascent in serum, pee and salivary cortisol and ACTH levels in patients with Cushing sickness — with either no change or an ascent in cortisol in patients with essential adrenal Cushing's condition. Along these lines, cortisol levels can't be utilized to survey the medication's viability in Cushing's condition. Since Cushing's disorder is moderately phenomenal, no medication has been tried in a randomized, fake treatment controlled preliminary.[6]

Table 1: Orphan Disease and Drug Used For Treatment.

Disease Name	Drug used	Manufactured By	Weblinks
ACROMEGALY	Octereotide	Novartis phar.co.	https://www.novartis.com/
	Pasiroetide	Novartis phar.co.	https://www.novartis.com/
	Lanreitide	IPSEN lnc.	https://www.ipsen.com/our-company/
CARCINOID TUMOR	Everolimus	Novartis phar.co.	https://www.novartis.com/
	Gallium(ga-68)	Novartis phar.co.	https://www.novartis.com/
CUSHING SYNDROME	Mifepristone	Corcept therapeutics	https://www.corcept.com
Gaucher disease	Imiglucerase	Genzyme Corporation	https://www.sanofi.com/en/your-health/specialty-care
	Taliglucerase alfa	Pfizer, Inc	https://www.pfizer.com/
	Miglustat	Actelion Pharmaceuticals Ltd	https://www.dnb.com/business-directory/company
Myelofibrosis	Ruxolitinib Phosphate	Incyte Corporation	https://www.incyte.com
Ovarian cancer	Doxorubicin HCL liposome	Medimmune Oncology, Inc	https://www.bloomberg.com/profile/company/0673798D:US
	Altretamine	AstraZeneca Pharmaceuticals LP	https://www.astrazeneca.com/
	Olaparib	Cytogen Corporation	https://www.crunchbase.com/organization/cytogen-corporation
Scurvy	Ascorbic acid	McGuff Pharmaceuticals Inc	https://www.mcguffpharmaceuticals.com/
Growth hormone deficiency	Somatropin	Pfizer, Inc	https://www.pfizer.com/
	Macimorelin acetate	Strongbridge Biopharma	https://strongbridgebio.com
Crohn's Disease	Adalimumab	AbbVie Inc	https://www.abbvie.com/
	Infliximab	Centocor, Inc	https://www.jnj.com/tag/centocor-inc

A variety of rare diseases has become a global issue for the nation. Some orphan diseases are from birth; mostly categorization is under the genomic disease than infection, viral and bacterial; some have no drugs to treat others have option surgery.[7] worldwide has its own nature of observing the thing different agency are recOgnised for introducing new drugs US FDA provides approval to drug prilimbiries are also taken by some non beneficial NGO which works in the welfare of the country they provide fundings to Rand D for the discovery of the drug.[8]

Table 2: Popularly known orphan disease.

• GALLBLADDER DISEASE	HUMAN PAPPILOMA VIRUS
• Acute intermittent porphyria.	CHANGE IN RBCS SHAPE
• Acute lymphoblastic leukemia.	CHAR SYNDROME
• Acute myeloid leukemia.	DISFUNCTION OF ORGAN
GLIOMA	GLYCOGEN STORAGE DISEASE
DEFICIENCY OF GROWTH HORMONE	DEFICIENCY OF VITAMIN C
LYSOZME STORAGE DISEASE	DISORDER OF KIDNEY
DELETION OF CHROMOSOME	HERPES
IODINE DEFICIENCY	DISARRANGEMENT OF SEX CHROMOSOME

Globally Drug Regulation

Medications that are assigned need audit have an FDA survey course of events objective of a half year, as opposed to the ten-month standard audit. While there were a couple of medications affirmed under this worldview in 1992, we started our investigation in 1993 to begin at a total year of information.[9] We have not had the option to distinguish the need for audit grouping of five orphan endorsements that happened during this period. Biologics are a significant piece of the orphan medication advancement, as certain uncommon infections require treatments dependent on biologics, for example, monoclonal antibodies, immunizations, and blood-based coagulation factors, among others.[10] Thus, it is imperative to comprehend the guidelines of biologics by the FDA In 2003, the FDA moved duty regarding audit and endorsement of most restorative biologics from CBER to CDER. In any case, the CBER keeps on managing antibodies, immunizing agents, serums, venoms, allergenic items, blood, and blood items. Contingent upon the classification of the item being created, the support can move toward the related association (Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development). In spite of the fact that the U.S. was the main nation to present Rare medication enactment in 1983, Japan, Australia, and the EU stuck to this same pattern before long. Anyway there are sure contrasts in how rare medications are taken care of in every one of them.[11]

European Drug Affairs

In any case, the joint endeavors at national and European levels, particularly by the EMEA, at last, proved to be fruitful on 16 December 1999, when the European parliament and board effectively surrounded the orphan medication guidelines. A devoted Committee of Orphan Medicinal Products inside the EMEA, involving people named by the European Member states, the European Commission, and patient affiliations, was framed with the objective of

looking at the medications applications and helping the commission in talks over medications[12] The uniqueness of this council lies in its comprehensive nature orphan medicines was affirmed on 16 December 1999 by the European Parliament and the Council.[13] The point was to build a Committee on Orphan Medicinal Products (COMP) as a subunit of the European Medicines Evaluation Agency (EMEA) which would support the biotechnological and pharmaceutical industry to find, create and advertise orphan medications. The risk of this board of trustees is looking into the applications for orphan items and helps the Commission to talk about uncommon illnesses. Each and everyone did not get sponsorship however there are certain rules and regulations of European federations to provide fundings.[14]

1. Logical counsel and conference during the advancement period of rare drugs
2. Complete decrease for convention help expense and follow-up fee
3. Complete waiver of charges for pre-approval examinations, half lessening in the new applications for promoting endorsement to huge measured undertakings, the complete waiver for not just showcasing.[15]

Us Drug Affairs

The Orphan Drug Act (ODA) accommodates conceding unique status to a medication or natural item ("sedate") to treat an uncommon ailment or endless supply of support. orphan assignment qualifies the backer of the medication for different improvement motivating forces of the ODA, including charge credits for qualified clinical testing. A showcasing application for a physician-recommended sedate item that has gotten assigned isn't dependent upon a professionally prescribed medication client charge except if the application incorporates a sign for something other than the uncommon illness or condition for which the medication was assigned.[16] The US ODA went in 1983 and consequently corrected in 1984, 1985, 1988, 1990, and 1992, was unmistakably brought out to organize the treatment of around 25 million American casualties of unpredicted sicknesses.[17,18] It was the primary solid positive development toward beating the obstacles that had ended up being the significant impediments in the advancement of orphan treatment until that point. By the arrangement of tremendous measure of motivations, the most conspicuous of which incorporates absolving the assigned rare item from paying new medication application expense, waivers for postapproval yearly foundation and items charges, arrangement of duty acknowledges on clinical research just as restrictive showcasing rights for up to the time of 7 years, ODA has gotten an immense.[19]

India Needs To Look Towards the Orphan Drugs Act and Affairs

The state of uncommon illness ought to be tended to by the Indian government right away. A reasonable enactment ought to be made for guidelines of orphan medicines. This would support the local pharmaceutical and biopharmaceutical enterprises of India to rapidly develop as a power to incorporate inside this noteworthy worldwide space.[20] Indian uncommon malady populace could be profited by such enactment. This huge number of patients enduring uncommon ailments ought not to be left to their own hopeless conditions with no thought and fix.[21] In any case, the predicament of the patients experiencing unexpected illnesses in India, can't be overlooked any longer, particularly considering the tenacious endeavors of different NGOs. Their endeavors, however incredibly estimable, are not feasible and need help from specialists. Accordingly, ample opportunity has already passed that the Indian Government woke up from its sleep and embraced measures to build up a thorough enactment as well as effectively went the additional mile of drawing in the drug organizations with motivations to advance the creation of native medications for the since a long time ago ignored Indian orphan infected patients.

The expanding mindfulness about orphan melodies and medications has tragically not permeated into the mind of the masses inside creating nations.[22] The boundless obliviousness, existent among the Indian clinical network. Further, this numbness can't be credited to an absence of harassed casualties. In the event that one is to pass by a couple of assessments, it is accepted that by virtue of being the second most crowded country on the planet, India has roughly 70 million cases of rare diseases. The way that we can't grasp the epidemiological effect of the maladies in India can be ascribed to the absence of an appropriate library of orphan illness cases. Considering this, the activities embraced by non-benefit non-government associations (NGOs), for example, ORDI is incredibly exemplary. It is by the righteousness of their endeavors that illnesses can be "informally" characterized as an ailment that influences 1 of every 5000 individuals or less in the Indian populace.[23] Other than ORDI, there exist a few different NGOs that are working in explicit ailment spaces, for example, the Foundation for Research on Rare Diseases and Disorders, Alzheimer's and Related Disorders Society of India, Down Syndrome Federation of India, Hemophilia Federation India, and so forth. Be that as it may, the nonappearance of any administration patronization or backing from the concerned specialists has put a central issue.[24]

Logical and persistent networks conveyed the necessities for government exercises toward unprecedented infection. The essential undertaking to join all masters of unprecedented contamination under a run of the mill stage was begun by INSA, which coordinated the first of the sort phenomenal illness workshop entitled "To Develop a Scientific Program for Research on Rare Diseases" in 2016, which considered on issues, for instance, which means of "Remarkable ailment explore streets, game plan structure for boosting and boosting creative work (R and D) attempts, and encompassing fitting sanctioning to ensure the commitment of the State in fulfilling the exceptional needs of extraordinary sicknesses. In the INSA remarkable disease workshop (2016), the decent prescription controller general of India communicated that a course of action for the animated opportunity of transient medicines and speedy track underwriting isn't up to date considering the way that organization needs clear recommendations as for the importance of phenomenal ailment, a framework for brisk track support (e.g., waiver of a specific stage in transient drug clinical preliminary.[25] He again communicated that inherited complexities in Indian people warrant Indian- focused examinations, as opposed to using data from concentrates in various countries. He likewise welcomed master proposals on the greed of evolution in the medications and restorative act to meet the prerequisites of research in uncommon illness.[26] The absence of interest in the Indian clinical local area with respect to orphan treatment has prompted helpless mindfulness among the overall population. Further, the visually impaired eye appeared by the concerned specialists to the predicament of a considerable Indian populace experiencing infections has prompted a feeling of disappointment and lack of engagement inside the Indian drug organization. Hence, the focal point of the Indian drug organizations lies more on the regular infections that have demonstrated to be an exceptionally worthwhile alternative throughout the long term.

Table 3: Commonly found the rare disease in India.

Disease	Per 100,000	Total Indian Population
Acatalasmia	3	36,000
Acromegly	5	60,000
Alkaptornuria	0.3	3,600
Alpa-1 antritrypsin	25	300,000
Grave disease	50	600,000
Parkinson disease	15	180,000

CONCLUSION

The orphan drug guidelines made by various nations have demonstrated as advertisers being developed of orphan medications. The orphan drug guideline in the US and the EU has been fruitful in furnishing medicines to patients with uncommon sicknesses This day situation concerning orphan medications among the created countries is a conspicuous difference to that in the agricultural countries like India. The acknowledgment that advancement of orphan medications would require an alternate methodology as the inborn idea of this undertaking is bound with significant expenses and fewer profits from the venture, prompted the improvement of different demonstrations in the created countries. These enactments furnished the drug organizations with the vital motivations to cause a change in outlook in their methodology toward orphan drugs.[27]

Be that as it may, the absence of enthusiasm for the Indian clinical network with respect to orphan medications has prompted poor mindfulness among the overall population. Further, the visually impaired eye appeared by the concerned specialists to the predicament of a considerable Indian populace experiencing illnesses has prompted a feeling of frustration and lack of engagement inside the Indian pharmaceutical system.[28]

The framework made by the ODA has prompted an expansion in the turn of events, endorsement, and accessibility of orphan items. While the market eliteness arrangement has extended access to medicines, it might be incorrectly giving restrictive market insurance to different items Hence, the different non-profitable NGO has to come up with different schemes and money landing on the company now, the rare disease can not be neglected furthermore for the welfare of the nation.[29,30]

DECLARATIONS

Funding: The study was not funded by any organization.

Conflicts of Interest: There are no conflicts of interest between the authors.

Availability of data and material: Not applicable.

Code availability: Not applicable

Authors' contributions: All work is done by corresponding author

Ethics approval: Not applicable.

Consent for Publication: All the authors have approved and reviewed the current manuscript for final publication

REFERENCES

1. Agarwal, Saurabh, Dipanjan Bhattacharjee, Navin Patil, and K. L. Bairy. "Orphan Drugs: The Current Global and Indian Scenario." Asian Journal of Pharmaceutical and Clinical Research, 2016; 9(4): 46–50.
2. Czech, Marcin, Aleksandra Baran-Kooiker, Kagan Atikeler, Maria Demirtshyan, Kamilla Gaitova, Malwina Holownia-Voloskova, Adina Turcu-Stiolica, et al. "A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries." Frontiers in Public Health, January, 2020; 7: 1–17. https://doi.org/10.3389/fpubh.2019.00416.
3. Drummond, Michael F., David A. Wilson, Panos Kanavos, Peter A. Ubel, and Joan Rovira. "Assessing the Economic Challenges Posed by Orphan Drugs: A Response to McCabe et Al. [2]." International Journal of Technology Assessment in Health Care, 2007; 23(3): 401–4. https://doi.org/10.1017/S0266462307071024.
4. Franco, Pedro. "Orphan Drugs: The Regulatory Environment." Drug Discovery Today, 2013; 18(3–4): 163–72. https://doi.org/10.1016/j.drudis.2012.08.009.
5. Gong, Shiwei, Yingxiao Wang, Xiaoyun Pan, Liang Zhang, Rui Huang, Xin Chen, Juanjuan Hu, Yi Xu, and Si Jin. "The Availability and Affordability of Orphan Drugs for Rare Diseases in China." Orphanet Journal of Rare Diseases, 2016; 11(1): 1–12. https://doi.org/10.1186/s13023-016-0392-4.
6. Korchagina, Daria, Aurelie Millier, Anne Lise Vataire, Samuel Aballea, Bruno Falissard, and Mondher Toumi. "Determinants of Orphan Drugs Prices in France: A Regression Analysis." Orphanet Journal of Rare Diseases, 2017; 12(1): 1–11. https://doi.org/10.1186/s13023-016-0561-5.
7. Mikami, Koichi. "Orphans in the Market: The History of Orphan Drug Policy." Social History of Medicine, 2019; 32(3): 609–30. https://doi.org/10.1093/shm/hkx098.
8. NISHITA. 2003. "Orphan Drugを正しい形で世に出し,広めるのは集中治療医の重要な役割である." Nihon Shuchu Chiryo Igakukai Zasshi. https://doi.org/10.3918/jsicm.10.325.
9. Onakpoya, Igho J., Elizabeth A. Spencer, Matthew J. Thompson, and Carl J. Heneghan. "Effectiveness, Safety and Costs of Orphan Drugs: An Evidence-Based Review." BMJ Open, 2015; 5(6). https://doi.org/10.1136/bmjopen-2014-007199.
10. Reddy, D. Saikiran, T. M. Pramodkumar, Yugendar Reddy, and K. Sirisha. "Orphan Regulations for Orphan Drug Development in India." Asian Journal of Pharmaceutics,

2014; 8(2): 130–32. https://doi.org/10.4103/0973-8398.134958.

11. Srivastava, G., and A. Winslow. "Orphan Drugs : Understanding the FDA Approval Process." Academic Entrepreneurship for Medical and Health Scientists, 2019; 1(3).
12. Stratford, Matthew. 2018. "Welcome to Mendeley: Quick Start Guide."
13. Sharma A, Jacob A, Tandon M, et al. Orphan drug: development trends and strategies. J Pharm Bioallied Sci., 2010; 2: 290–9.
14. European Medicines Agency (EMA). Orphan drugs and rare diseases at a glance. http://www.ema.europa.eu/docs/en_GB/ document_library/Other/2010/01/WC500069805.pdf
15. https://www.tga.gov.au/node/758474
16. National Institute for Clinical Excellence. NICE citizens council report ultra orphan drugs. London: NICE, 2004. http://www.nice.org.uk/ proxy/?sourceUrl=http://www.nice.org.uk/niceMedia/pdf/ boardmeeting/brdjan05item4.pdf (accessed 7 May 2015).
17. Vikaas, Budhwar, Singh Ajay K, and Choudhary Manjusha. "Regulations of Orphan Drugs in Usa, Eu and India – a Comparative Study." International Journal of Drug Regulatory Affairs, 2016; 4(3): 30–37.
18. Thaker, Z. "ORPHAN DRUGS: OVERVIEW AND REGULATORY REVIEW PROCESS Z. Thaker*, K. Jethva, D. Bhatt, M. Zaveri and S. Deshpande K. B. Institute of Pharmaceutical Education and Research, Near GH - 6 Circle, Sector - 23, Gandhinagar - 382023, Gujarat, India." 2019; 10(2): 505–18.
19. Haffner, Marlene E., and John V. Kelsey. "Evaluation of Orphan Products by the U.S. Food and Drug Administration." International Journal of Technology Assessment in Health Care, 1992; 8(4): 647–57.
20. European Union. Commission Regulation (EC) No 2003/C 178/02 of the European Parliament. Official Journal of the European Communities [Internet], 2003; [cited2016 May 4]; L178:1-7. Available from:
21. lex.europa.eu/LexUriServ/LexUriServ.do? uri=OJ:C:2003:178:0002:0008:EN:PDF 17. Gajra BB and Limbachiya S. Absence of Regulations for Orphan Drugs in India: Ignorance of the Government [Internet]. 2015 [cited 2016 May 7] Available from: https://aapsblog.aaps.org/2015/05/13/absence-ofregulations-for-orphan-drugs-in-india-ignorance-ofthe-government/
22. Divya VC and Sathasivasubramanian S. Submandibular Sialolithiasis - A report of two cases. The Journal of Medical Research, 2015; 1(1): 05-07.

23. Hathaway C, Manthei J, Scherer CZ. Food and Drug Law Institute, 2009; 3: 20. Janodia MD, Chauhan A, Hakak SM, Sreedhar D, Ligade VS, Udupa N. Data Exclusivity Provisions in India: Impact on Public Health. Journal of Intellectual Property Rights. 2008;13 (5):442–6.
24. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet, 2008; 371(9629): 2039-41.
25. Available from: http://www.fda.gov/fdac/features/1999/399_orph. html#tv.
26. Kataria MK, Garg M, Anand V, Bilandi A, Kukkar V, Bhandari A. An insight on regulations governing orphan diseases and drugs. Res J Pharm Biol Chem Sci., 2011; 2(3): 373-84.
27. Bigoniya P. Implementation of orphan drug regulation in India: The need of the time. Pharm Rev 2010:83-7. Available from: http://www. kppub.com/articles/may2010/implementation_of_orphan_drug_ regulation_in_india.html.
28. Reddy DS, Pramodkumar TM, Reddy Y, Sirisha K. Orphan regulations for orphan drug development in India. Asian J Pharm., 2014; 8: 130-2.
29. Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H and Raine J: The risks of risk aversion in drug regulation. Nature reviews Drug discovery, 2013; 12(12): 907.
30. Sharma A, Jacob A, Tandon M and Kumar D: Orphan drug: development trends and strategies. Journal of Pharmacy and Bioallied Sciences, 2010; 2(4): 290.